Delving into the Latest Updates on UniCAR02-T(Cellex Patient Treatment) with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [2]

Active Indication-

Inactive Indication

Breast CancerColorectal CancerKidney Neoplasms+ [3]

Originator Organization

Cellex Patient Treatment GmbH

Active Organization-

Inactive Organization

AvenCell Europe GmbHStartupCellex Patient Treatment GmbH

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-pPSMA in patients with progressive disease after standard systemic therapy in castration-resistant prostate cancers with positive PSMA marker. The UniCAR02-T-pPSMA drug is a combination of a cellular component (UniCAR02-T) with a recombinant antibody derivative (TMpPSMA) which together forms the active drug.

Start Date23 Nov 2020

Sponsor / Collaborator

AvenCell Europe GmbHStartup

[+1]

NCT04230265

/ RecruitingPhase 1

Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With CD123 Target Module (TM123) for the Treatment of Patients With Hematologic and Lymphatic Malignancies Positive for CD123

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and lymphatic malignancies positive for CD123 marker. The UniCAR02-T-CD123 drug is a combination of a cellular component (UniCAR02-T) with a recombinant antibody derivative (TM123) which together forms the active drug.

Start Date28 Jan 2020

Sponsor / Collaborator

AvenCell Europe GmbHStartup

[+1]

100 Clinical Results associated with UniCAR02-T(Cellex Patient Treatment)

Login to view more data

100 Translational Medicine associated with UniCAR02-T(Cellex Patient Treatment)

Login to view more data

100 Patents (Medical) associated with UniCAR02-T(Cellex Patient Treatment)

Login to view more data

100 Deals associated with UniCAR02-T(Cellex Patient Treatment)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Cell Carcinoma	Phase 1	DE	Cellex Patient Treatment GmbH	23 Nov 2020
Breast Cancer	Phase 1	DE	-	18 Nov 2020
Colorectal Cancer	Phase 1	DE	-	18 Nov 2020
Kidney Neoplasms	Phase 1	DE	-	18 Nov 2020
Non-Small Cell Lung Cancer	Phase 1	DE	-	18 Nov 2020
Prostatic Cancer	Phase 1	DE	-	18 Nov 2020
Prostatic Cancer	Phase 1	DE	-	18 Nov 2020